Viridian Therapeutics (VRDN) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free VRDN Stock Alerts $14.63 +0.36 (+2.52%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | markets.businessinsider.comViridian Therapeutics (VRDN) Gets a Buy from Stifel NicolausMay 13, 2024 | americanbankingnews.comLifesci Capital Weighs in on Viridian Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:VRDN)May 13, 2024 | americanbankingnews.comQ2 2024 Earnings Forecast for Viridian Therapeutics, Inc. (NASDAQ:VRDN) Issued By HC WainwrightMay 13, 2024 | americanbankingnews.comBrokers Set Expectations for Viridian Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VRDN)May 13, 2024 | americanbankingnews.comB. Riley Comments on Viridian Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VRDN)May 13, 2024 | americanbankingnews.comViridian Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.80) Per Share (NASDAQ:VRDN)May 12, 2024 | americanbankingnews.comViridian Therapeutics, Inc. (NASDAQ:VRDN) to Post FY2027 Earnings of $5.33 Per Share, Wedbush ForecastsMay 12, 2024 | americanbankingnews.comFY2028 EPS Estimates for Viridian Therapeutics, Inc. (NASDAQ:VRDN) Cut by Leerink PartnrsMay 12, 2024 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Cut to Neutral at LADENBURG THALM/SH SHMay 12, 2024 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Earns Buy Rating from Needham & Company LLCMay 12, 2024 | americanbankingnews.comHC Wainwright Trims Viridian Therapeutics (NASDAQ:VRDN) Target Price to $27.00May 12, 2024 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Cut to "Neutral" at B. RileyMay 12, 2024 | americanbankingnews.comOppenheimer Trims Viridian Therapeutics (NASDAQ:VRDN) Target Price to $31.00May 11, 2024 | americanbankingnews.comAnalysts Offer Predictions for Viridian Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:VRDN)May 11, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)May 10, 2024 | marketbeat.comFY2028 EPS Estimates for Viridian Therapeutics, Inc. Reduced by Analyst (NASDAQ:VRDN)Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at Leerink Partnrs decreased their FY2028 earnings per share estimates for Viridian Therapeutics in a note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now forecasts that the companMay 10, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating for Viridian Therapeutics Amid Positive Clinical Progress and Strategic BLA Submission PlanMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amidst Accelerated Clinical Progress and Market Expansion PotentialMay 10, 2024 | businesswire.comViridian Therapeutics to Participate in Upcoming May Investor ConferencesMay 10, 2024 | msn.comLadenburg Thalmann Downgrades Viridian Therapeutics (VRDN)May 10, 2024 | americanbankingnews.comViridian Therapeutics (NASDAQ:VRDN) Shares Gap Down Following Analyst DowngradeMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics on Strong Clinical Trials and Promising Drug ProspectsMay 9, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Given New $27.00 Price Target at HC WainwrightHC Wainwright lowered their target price on shares of Viridian Therapeutics from $37.00 to $27.00 and set a "buy" rating for the company in a research note on Thursday.May 9, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Shares Gap Down on Analyst DowngradeViridian Therapeutics (NASDAQ:VRDN) Shares Gap Down Following Analyst DowngradeMay 9, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Posts Quarterly Earnings Results, Beats Estimates By $0.28 EPSViridian Therapeutics (NASDAQ:VRDN - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.28. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.09 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. The firm's revenue was down 26.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.61) EPS.May 9, 2024 | msn.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Stock Rating Lowered by LADENBURG THALM/SH SHLADENBURG THALM/SH SH downgraded Viridian Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday.May 9, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Rating Reiterated by Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $30.00 price objective on shares of Viridian Therapeutics in a research note on Thursday.May 9, 2024 | finance.yahoo.comViridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 9, 2024 | finance.yahoo.comViridian Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amidst Strong Pipeline Progress and Solid Financial StandingMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics on Promising VRDN-001 Trials and Strong Financial OutlookMay 8, 2024 | finance.yahoo.comViridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical AdvancementsMay 8, 2024 | investorplace.comVRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | seekingalpha.comViridian Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 8, 2024 | businesswire.comViridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | globenewswire.comPacific Urban Investors Expands Denver Portfolio with Acquisition of Viridian Apartment Community in Greenwood VillageMay 3, 2024 | businesswire.comViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | marketbeat.comViridian Therapeutics (VRDN) Set to Announce Quarterly Earnings on WednesdayViridian Therapeutics (NASDAQ:VRDN) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=591036)April 29, 2024 | businesswire.comViridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024April 24, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 6.2%Viridian Therapeutics (NASDAQ:VRDN) Shares Down 6.2%April 21, 2024 | marketbeat.comKnights of Columbus Asset Advisors LLC Boosts Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Knights of Columbus Asset Advisors LLC grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 420.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 153,949 shares of the companApril 19, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading VolumeViridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading VolumeApril 13, 2024 | fool.comViridian Therapeutics (NASDAQ: VRDN)April 11, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. lessened its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 5.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,448,015 shares of the company's stockApril 10, 2024 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Trading Down 7.5%Viridian Therapeutics (NASDAQ:VRDN) Trading Down 7.5%April 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Viridian Therapeutics Amidst TED Treatment Market PotentialApril 4, 2024 | businesswire.comViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of "Buy" from BrokeragesViridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has been assigned a consensus recommendation of "Buy" from the ten analysts that are presently covering the firm, MarketBeat reports. Ten research analysts have rated the stock with a buy rating. The average 12-month target price among anApril 1, 2024 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by SG Americas Securities LLCSG Americas Securities LLC decreased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 60.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,588 shares of the company's stoc Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address “Dollar Will Be Worth NOTHING” -Musk (Ad)Elon Musk just issued an urgent warning… Saying “The U.S. Dollar will be worth NOTHING…” As "stealth money printing" pushes the price of Bitcoin, Ethereum, XRP and crypto higher. Click here to claim your free seat ticket now. VRDN Media Mentions By Week VRDN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼0.290.54▲Average Medical News Sentiment VRDN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼464▲VRDN Articles Average Week Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CSTL News Today FLGT News Today CDNA News Today CELC News Today VCYT News Today SERA News Today PMD News Today GH News Today ARWR News Today FTRE News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRDN) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsObama’s Forever Term [exposed]Porter & CompanyThe 1,000X Crypto PlaybookTrue Market InsidersUrgent Nvidia WarningAltimetryCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
